The Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H), Ministry of Ayush, has successfully concluded a five-day National Capacity Building Training Programme aimed at strengthening quality assurance, standardization and regulatory compliance in the Ayurveda, Siddha, Unani and Homoeopathy (ASU&H) drug sector. The programme was held from November 24–28, 2025, bringing together Drug Enforcement Officers, Quality Control Personnel and manufacturers from across the country.
The training combined expert lectures, demonstrations and field visits. Over the first two days, participants attended in-depth technical sessions on NABL accreditation, Quality Management Systems, Good Manufacturing Practices, and pharmacognostic, physicochemical and phytochemical evaluation of herbal drugs. Day three featured sessions on shelf-life studies and regulatory frameworks, followed by visits to leading manufacturing facilities, including Dr. Willmar Schwabe India Pvt. Ltd. in Noida and Hamdard Laboratories in Ghaziabad.
Microbiological and pharmacological evaluation, regulatory aspects and hands-on lab training were the focus on the fourth day, along with a visit to an herbal garden. The final day covered pharmacopoeial standards, metal and mineral drug standardization, and modern instrumentation used in ASU&H drug testing.
A total of 37 participants from regulatory bodies, research councils, pharma industries and academic institutions took part, gaining practical exposure to the latest advancements in quality testing and standardization in traditional medicine.
The valedictory session was addressed by Prof. (Dr.) B. L. Mehra, Chairperson of the National Commission for Indian System of Medicine, along with senior officials including Dr. Jai Prakash from the Indian Pharmacopoeia Commission, Dr. Ravinder Singh from FSSAI, and Dr. Raman Mohan Singh, Director, PCIM&H. Speakers highlighted the need for rigorous quality control, global benchmarks and scientific validation to boost the credibility of Indian traditional medicine systems.
Participants lauded the programme for its mix of theory, practical training and field exposure, noting that it significantly deepened their understanding of pharmacopoeial standards, GMP and regulatory processes. The initiative is expected to give strong momentum to national efforts toward building a robust quality assurance ecosystem for ASU&H drugs.
Also Read